Mallinckrodt Pharmaceuticals' OFIRMEV
injection has received a Prior Approval Supplement from the U.S. Food and Drug Administration.
OFIREMEV will now be available in an
intravenous bag, giving an additional method of delivery to health care
providers.
The Prior Approval Supplement will include the new container closure and the
manufacturer of the product being added. Fresenius Kabi will take on the job of
manufacturing the polypropylene bags.
Mallinckrodt expects the product to hit the market
in the second quarter of 2017.
OFIRMEV approved for Prior Approval Supplement
Alerts Sign-up